<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02649556</url>
  </required_header>
  <id_info>
    <org_study_id>ZRHR-ERS-09-EXT-US</org_study_id>
    <secondary_id>ZRHR-ERS-09-EXT-US</secondary_id>
    <nct_id>NCT02649556</nct_id>
  </id_info>
  <brief_title>A 26-week Extension of the ZRHR-ERS-09-US Study Evaluating Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2</brief_title>
  <official_title>A 26-week Extension Study to Determine the Biological and Functional Changes in Healthy Smokers Who Switched From Conventional Cigarettes (CC) to Tobacco Heating System 2.2 (THS 2.2) Compared to Those Who Continued to Smoke CC in the ZRHR-ERS-09-US Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philip Morris Products S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philip Morris Products S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the ZRHR-ERS-09-EXT-US study is to further assess the effect of the Tobacco&#xD;
      Heating System 2.2 (THS 2.2), a candidate Modified Risk Tobacco Product, compared to&#xD;
      conventional cigarettes (CC) on the components of the &quot;smokers' health profile&quot; for a&#xD;
      prolonged period of 26 weeks, providing additional information to the results of the original&#xD;
      study ZRHR-ERS-09-US of 26-week exposure (NCT02396381). In total, the ZRHR-ERS-09-EXT-US&#xD;
      study will extend the exposure period to 52 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ZRHR-ERS-09-EXT-US study is a 26-week extension of the original study ZRHR-ERS-09-US.&#xD;
&#xD;
      The subjects in the Full Analysis Set - As Exposed (FAS-EX) included subjects for combined&#xD;
      analyses from the original six month study (ZRHR-ERS-09-US ) who did not enter the extension&#xD;
      study (ZRHR-ERS-09-EXT-US).&#xD;
&#xD;
      This study was conducted as a separate investigation, as a follow-up of the randomized&#xD;
      exposure period of the original study, extending the exposure from Week 26 (Visit 10 [V10])&#xD;
      to Week 52 (Visit 16 [V16]), and using the same sites.&#xD;
&#xD;
      Subjects continued to use the product they were randomized to in the original study&#xD;
      ZRHR-ERS-09-US (THS 2.2 arm or CC arm).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 30, 2015</start_date>
  <completion_date type="Actual">December 20, 2017</completion_date>
  <primary_completion_date type="Actual">March 13, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Levels of High Density Lipoprotein C (HDL-C).</measure>
    <time_frame>52 weeks</time_frame>
    <description>Concentrations (mg/dL) measured in serum. Mean values are provided as descriptive statistics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Levels of White Blood Cells (WBC).</measure>
    <time_frame>52 weeks</time_frame>
    <description>Total count in blood (GI/L). Mean values are provided as descriptive statistics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1).</measure>
    <time_frame>52 weeks</time_frame>
    <description>FEV1 post-bronchodilator and expressed as percentage predicted (FEV1 %pred). Mean values are provided as descriptive statistics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of Soluble Intercellular Adhesion Molecule 1 (sICAM-1).</measure>
    <time_frame>52 weeks</time_frame>
    <description>Concentrations (ng/mL) measured in serum. Geometric Mean values are provided as descriptive statistics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of 11-dehydrothromboxane B2 (11-DTXB2).</measure>
    <time_frame>52 weeks</time_frame>
    <description>Concentrations measured in urine and expressed as concentration adjusted for creatinine (pg/mg creat). Geometric Mean values are provided as descriptive statistics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of 8-epi-prostaglandin F2α (8-epi-PGF2α).</measure>
    <time_frame>52 weeks</time_frame>
    <description>Concentrations measured in urine and expressed as concentration adjusted for creatinine (pg/mg creat). Geometric Mean values are provided as descriptive statistics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of Total 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (Total NNAL).</measure>
    <time_frame>52 weeks</time_frame>
    <description>Concentrations measured in urine and expressed as concentration adjusted for creatinine (pg/mg creat). Geometric Mean values are provided as descriptive statistics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Levels of Carboxyhemoglobin (COHb).</measure>
    <time_frame>52 weeks</time_frame>
    <description>Carboxyhemoglobin (COHb) is assayed from whole blood. Expressed as % of saturation of hemoglobin. Geometric Mean values are provided as descriptive statistics.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">672</enrollment>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>THS 2.2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad libitum use of THS 2.2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ad libitum use of CC</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>THS 2.2</intervention_name>
    <description>Ad libitum use of THS 2.2 in an ambulatory setting for 26 weeks.</description>
    <arm_group_label>THS 2.2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CC</intervention_name>
    <description>Ad libitum use of CC in an ambulatory setting for 26 weeks.&#xD;
The subject's own preferred brands of CC (no brand restriction) continue to be used as the reference product.</description>
    <arm_group_label>CC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject completed V10 of the original study (ZRHR-ERS-09-US).&#xD;
&#xD;
          -  The subject is willing to comply to study procedures and to continue to use the&#xD;
             product he/she was allocated to during the original study (THS 2.2 or CC) for an&#xD;
             additional 26 weeks at V10.&#xD;
&#xD;
          -  Subject has given written informed consent to enter the 26-week extension study at&#xD;
             V10.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically relevant medical conditions that in the opinion of the investigators would&#xD;
             jeopardize the safety of the participant.&#xD;
&#xD;
          -  As per judgment of the PI(s) or designee(s), the subject cannot participate in the&#xD;
             study for any reason (e.g. medical, psychiatric and/or social reason).&#xD;
&#xD;
          -  Subject has made an attempt to quit using tobacco-containing products (e.g. CC and THS&#xD;
             2.2) during the original study.&#xD;
&#xD;
          -  Female subject is pregnant or breast feeding.&#xD;
&#xD;
          -  Female subject who does not agree to use an acceptable method of effective&#xD;
             contraception.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christelle Haziza, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Philip Morris Products S.A.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Danielle Armas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Celerion Arizona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leonard Dunn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research West Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hugh Coleman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Stoica, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Compass Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Adams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Kentucky Research Associate</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Davidson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Celerion Lincoln</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Rubino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PMG Research of Raleigh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Raad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PMG Research of Charlotte</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin Cannon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PMG Research of Wilmington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Derek Schroder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PMG Research of Cary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephanie Powell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PMG Research of Bristol</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NOCCR</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Darrell Herrington, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Benchmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurence Chu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Benchmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Seger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Benchmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Subich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Compass Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lon Lynn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research West Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabel Kuhare-Arcure, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Midwest Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Keith Scott, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion Arizona</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research West Florida</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance, Inc</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research West Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research</name>
      <address>
        <city>The Villages</city>
        <state>Florida</state>
        <zip>32162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Kentucky Research Associate</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Celerion Lincoln</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Cary</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Raleigh</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Bristol</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NOCCR</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark</name>
      <address>
        <city>San Angelo</city>
        <state>Texas</state>
        <zip>76904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Clinical Research</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 5, 2016</study_first_submitted>
  <study_first_submitted_qc>January 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2016</study_first_posted>
  <results_first_submitted>May 25, 2020</results_first_submitted>
  <results_first_submitted_qc>November 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 4, 2020</results_first_posted>
  <last_update_submitted>November 10, 2020</last_update_submitted>
  <last_update_submitted_qc>November 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Modified risk tobacco product</keyword>
  <keyword>Conventional cigarette</keyword>
  <keyword>Exposure response</keyword>
  <keyword>Smoking</keyword>
  <keyword>Tobacco Heating System</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 23, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT02649556/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 8, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT02649556/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Of the 984 subjects (488 in the THS arm and 496 in the CC arm) who were enrolled and randomized into the original study, NCT02396381, 672 subjects were enrolled into the extension study (309 in the THS arm and 363 in the CC arm).</recruitment_details>
      <pre_assignment_details>672 subjects enrolled in the extension study; the 857 subjects in the Full Analysis Set - As Exposed (FAS-EX) included subjects for combined analyses from the original six month study who did not enter the extension study. The analysis was performed according to subjects' exposure over the 12 month period as detailed in &quot;Arm/Group&quot; (Reporting Groups) table.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>THS 2.2 Use</title>
          <description>This reporting group comprised 230 subjects. The &quot;THS 2.2 use&quot; product use category was defined as THS use of 70% or more over the entire analysis period. (≥1 THS 2.2 or CC, and ≥70% THS 2.2 use over the analysis period, and ≥70% THS 2.2 use on &gt;50% of days in the analysis period.)</description>
        </group>
        <group group_id="P2">
          <title>CC Use</title>
          <description>This reporting group comprised 424 subjects. The &quot;CC use&quot; product use category was defined as THS use of less than 1% over the entire analysis period. (≥1 THS 2.2 or CC use, and &lt;1% THS 2.2 use over the entire analysis period and &lt;1% THS 2.2 use on ≥ 50% of days in the analysis period.)</description>
        </group>
        <group group_id="P3">
          <title>Dual Use</title>
          <description>This reporting group comprised 152 subjects. The &quot;Dual use&quot; product use category was defined as THS use of less than 70% over the entire analysis period. (≥ 1 THS 2.2 or CC and, 1% ≤THS 2.2 &lt;70% over the analysis period, or THS 2.2-use and CC use categories do not apply to 50% of these days.)</description>
        </group>
        <group group_id="P4">
          <title>Other Use</title>
          <description>This reporting group comprised 51 subjects. &quot;Other use&quot; refers to any other product use over the entire analysis period. (Subjects with missing product use data, subjects using e-cigarettes or other tobacco products, quitters, or subjects who switched across different use patterns.)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="230"/>
                <participants group_id="P2" count="424"/>
                <participants group_id="P3" count="152"/>
                <participants group_id="P4" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="167"/>
                <participants group_id="P2" count="312"/>
                <participants group_id="P3" count="102"/>
                <participants group_id="P4" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="112"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>THS 2.2 Use</title>
          <description>The &quot;THS 2.2 use&quot; product use category was defined as THS use of 70% or more over the entire analysis period.&#xD;
(≥1 THS 2.2 or CC, and ≥70% THS 2.2 use over the analysis period, and ≥70% THS 2.2 use on &gt;50% of days in the analysis period.)</description>
        </group>
        <group group_id="B2">
          <title>CC Use</title>
          <description>The &quot;CC use&quot; product use category was defined as THS use of less than 1% over the entire analysis period.&#xD;
(≥1 THS 2.2 or CC use, and &lt;1% THS 2.2 use over the entire analysis period and &lt;1% THS 2.2 use on ≥ 50% of days in the analysis period.)</description>
        </group>
        <group group_id="B3">
          <title>Dual Use</title>
          <description>The &quot;Dual use&quot; product use category was defined as THS use of less than 70% over the entire analysis period.&#xD;
(≥ 1 THS 2.2 or CC and, 1% ≤THS 2.2 &lt;70% over the analysis period, or THS 2.2-use and CC use categories do not apply to 50% of these days.)</description>
        </group>
        <group group_id="B4">
          <title>Other Use</title>
          <description>&quot;Other use&quot; refers to any other product use over the entire analysis period. (Subjects with missing product use data, subjects using e-cigarettes or other tobacco products, quitters, or subjects who switched across different use patterns.)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="230"/>
            <count group_id="B2" value="424"/>
            <count group_id="B3" value="152"/>
            <count group_id="B4" value="51"/>
            <count group_id="B5" value="857"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.8" spread="9.68"/>
                    <measurement group_id="B2" value="45.2" spread="9.54"/>
                    <measurement group_id="B3" value="44.2" spread="9.76"/>
                    <measurement group_id="B4" value="44.5" spread="8.21"/>
                    <measurement group_id="B5" value="44.6" spread="9.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="180"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="353"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                    <measurement group_id="B2" value="244"/>
                    <measurement group_id="B3" value="85"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="213"/>
                    <measurement group_id="B2" value="396"/>
                    <measurement group_id="B3" value="146"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="804"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="151"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="182"/>
                    <measurement group_id="B2" value="338"/>
                    <measurement group_id="B3" value="123"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="679"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.0" spread="4.06"/>
                    <measurement group_id="B2" value="27.1" spread="4.13"/>
                    <measurement group_id="B3" value="26.9" spread="4.25"/>
                    <measurement group_id="B4" value="26.6" spread="4.91"/>
                    <measurement group_id="B5" value="27.0" spread="4.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Levels of High Density Lipoprotein C (HDL-C).</title>
        <description>Concentrations (mg/dL) measured in serum. Mean values are provided as descriptive statistics.</description>
        <time_frame>52 weeks</time_frame>
        <population>Full Analysis Set - As Exposed Analysis (FAS-EX). Some participants were excluded from analysis for protocol deviations (including, but not limited to, missing measurements).</population>
        <group_list>
          <group group_id="O1">
            <title>THS 2.2 Use</title>
            <description>The &quot;THS 2.2 use&quot; product use category was defined as THS use of 70% or more over the entire analysis period.&#xD;
(≥1 THS 2.2 or CC, and ≥70% THS 2.2 use over the analysis period, and ≥70% THS 2.2 use on &gt;50% of days in the analysis period.)</description>
          </group>
          <group group_id="O2">
            <title>CC Use</title>
            <description>The &quot;CC use&quot; product use category was defined as THS use of less than 1% over the entire analysis period.&#xD;
(≥1 THS 2.2 or CC use, and &lt;1% THS 2.2 use over the entire analysis period and &lt;1% THS 2.2 use on ≥ 50% of days in the analysis period.)</description>
          </group>
          <group group_id="O3">
            <title>Dual Use</title>
            <description>The &quot;Dual use&quot; product use category was defined as THS use of less than 70% over the entire analysis period.&#xD;
(≥ 1 THS 2.2 or CC and, 1% ≤THS 2.2 &lt;70% over the analysis period, or THS 2.2-use and CC use categories do not apply to 50% of these days.)</description>
          </group>
          <group group_id="O4">
            <title>Other Use</title>
            <description>&quot;Other use&quot; refers to any other product use over the entire analysis period. (Subjects with missing product use data, subjects using e-cigarettes or other tobacco products, quitters, or subjects who switched across different use patterns.)</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of High Density Lipoprotein C (HDL-C).</title>
          <description>Concentrations (mg/dL) measured in serum. Mean values are provided as descriptive statistics.</description>
          <population>Full Analysis Set - As Exposed Analysis (FAS-EX). Some participants were excluded from analysis for protocol deviations (including, but not limited to, missing measurements).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="315"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2" lower_limit="49.5" upper_limit="54.8"/>
                    <measurement group_id="O2" value="50.6" lower_limit="48.9" upper_limit="52.3"/>
                    <measurement group_id="O3" value="54.0" lower_limit="49.7" upper_limit="58.4"/>
                    <measurement group_id="O4" value="54.7" lower_limit="49.2" upper_limit="60.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis will determine the effect of THS 2.2 compared to CC at Month 12 on the components of the &quot;smokers' health profile&quot;. This study has no formal pre-specified hypotheses associated with the study objectives. Estimates of THS 2.2 effect will be presented by mean of LS Mean difference of HDL-C levels between CC and THS 2.2 and related 95% CI.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.160</ci_lower_limit>
            <ci_upper_limit>3.65</ci_upper_limit>
            <other_analysis_desc>Mixed model conducted on original values with visit, baseline value and its interaction with visit, sex, Caucasian origin, product use pattern category and its interaction with visit, and other baseline covariates relevant for the specific clinical risk endpoint as fixed effect factors and site as a random effect.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Levels of White Blood Cells (WBC).</title>
        <description>Total count in blood (GI/L). Mean values are provided as descriptive statistics.</description>
        <time_frame>52 weeks</time_frame>
        <population>Full Analysis Set - As Exposed Analysis (FAS-EX). Some participants were excluded from analysis for protocol deviations (including, but not limited to, missing measurements).</population>
        <group_list>
          <group group_id="O1">
            <title>THS 2.2 Use</title>
            <description>The &quot;THS 2.2 use&quot; product use category was defined as THS use of 70% or more over the entire analysis period.&#xD;
(≥1 THS 2.2 or CC, and ≥70% THS 2.2 use over the analysis period, and ≥70% THS 2.2 use on &gt;50% of days in the analysis period.)</description>
          </group>
          <group group_id="O2">
            <title>CC Use</title>
            <description>The &quot;CC use&quot; product use category was defined as THS use of less than 1% over the entire analysis period.&#xD;
(≥1 THS 2.2 or CC use, and &lt;1% THS 2.2 use over the entire analysis period and &lt;1% THS 2.2 use on ≥ 50% of days in the analysis period.)</description>
          </group>
          <group group_id="O3">
            <title>Dual Use</title>
            <description>The &quot;Dual use&quot; product use category was defined as THS use of less than 70% over the entire analysis period.&#xD;
(≥ 1 THS 2.2 or CC and, 1% ≤THS 2.2 &lt;70% over the analysis period, or THS 2.2-use and CC use categories do not apply to 50% of these days.)</description>
          </group>
          <group group_id="O4">
            <title>Other Use</title>
            <description>&quot;Other use&quot; refers to any other product use over the entire analysis period. (Subjects with missing product use data, subjects using e-cigarettes or other tobacco products, quitters, or subjects who switched across different use patterns.)</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of White Blood Cells (WBC).</title>
          <description>Total count in blood (GI/L). Mean values are provided as descriptive statistics.</description>
          <population>Full Analysis Set - As Exposed Analysis (FAS-EX). Some participants were excluded from analysis for protocol deviations (including, but not limited to, missing measurements).</population>
          <units>GI/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="312"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.73" lower_limit="6.47" upper_limit="6.99"/>
                    <measurement group_id="O2" value="7.31" lower_limit="7.07" upper_limit="7.54"/>
                    <measurement group_id="O3" value="7.28" lower_limit="6.85" upper_limit="7.71"/>
                    <measurement group_id="O4" value="7.57" lower_limit="6.85" upper_limit="8.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis will determine the effect of THS 2.2 compared to CC at Month 12 on the components of the &quot;smokers' health profile&quot;. This study has no formal pre-specified hypotheses associated with the study objectives. Estimates of THS 2.2 effect will be presented by mean of LS Mean difference of White Blood Cell counts between CC and THS 2.2 and related 95% CI.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.413</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.694</ci_lower_limit>
            <ci_upper_limit>-0.131</ci_upper_limit>
            <other_analysis_desc>Mixed model conducted on original values with visit, baseline value and its interaction with visit, sex, Caucasian origin, product use pattern category and its interaction with visit, and other baseline covariates relevant for the specific clinical risk endpoint as fixed effect factors and site as a random effect.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1).</title>
        <description>FEV1 post-bronchodilator and expressed as percentage predicted (FEV1 %pred). Mean values are provided as descriptive statistics.</description>
        <time_frame>52 weeks</time_frame>
        <population>Full Analysis Set - As Exposed Analysis (FAS-EX). Some participants were excluded from analysis for protocol deviations (including, but not limited to, missing measurements).</population>
        <group_list>
          <group group_id="O1">
            <title>THS 2.2 Use</title>
            <description>The &quot;THS 2.2 use&quot; product use category was defined as THS use of 70% or more over the entire analysis period.&#xD;
(≥1 THS 2.2 or CC, and ≥70% THS 2.2 use over the analysis period, and ≥70% THS 2.2 use on &gt;50% of days in the analysis period.)</description>
          </group>
          <group group_id="O2">
            <title>CC Use</title>
            <description>The &quot;CC use&quot; product use category was defined as THS use of less than 1% over the entire analysis period.&#xD;
(≥1 THS 2.2 or CC use, and &lt;1% THS 2.2 use over the entire analysis period and &lt;1% THS 2.2 use on ≥ 50% of days in the analysis period.)</description>
          </group>
          <group group_id="O3">
            <title>Dual Use</title>
            <description>The &quot;Dual use&quot; product use category was defined as THS use of less than 70% over the entire analysis period.&#xD;
(≥ 1 THS 2.2 or CC and, 1% ≤THS 2.2 &lt;70% over the analysis period, or THS 2.2-use and CC use categories do not apply to 50% of these days.)</description>
          </group>
          <group group_id="O4">
            <title>Other Use</title>
            <description>&quot;Other use&quot; refers to any other product use over the entire analysis period. (Subjects with missing product use data, subjects using e-cigarettes or other tobacco products, quitters, or subjects who switched across different use patterns.)</description>
          </group>
        </group_list>
        <measure>
          <title>Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1).</title>
          <description>FEV1 post-bronchodilator and expressed as percentage predicted (FEV1 %pred). Mean values are provided as descriptive statistics.</description>
          <population>Full Analysis Set - As Exposed Analysis (FAS-EX). Some participants were excluded from analysis for protocol deviations (including, but not limited to, missing measurements).</population>
          <units>Percent of predicted FEV1</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="288"/>
                <count group_id="O3" value="95"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.2" lower_limit="91.1" upper_limit="95.2"/>
                    <measurement group_id="O2" value="92.3" lower_limit="90.7" upper_limit="94.0"/>
                    <measurement group_id="O3" value="91.1" lower_limit="88.2" upper_limit="94.1"/>
                    <measurement group_id="O4" value="95.2" lower_limit="90.1" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis will determine the effect of THS 2.2 compared to CC at Month 12 on the components of the &quot;smokers' health profile&quot;. This study has no formal pre-specified hypotheses associated with the study objectives. Estimates of THS 2.2 effect will be presented by mean of LS Mean difference of FEV1 levels between CC and THS 2.2 and related 95% CI.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.914</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.339</ci_lower_limit>
            <ci_upper_limit>2.17</ci_upper_limit>
            <other_analysis_desc>Mixed model conducted on original values with visit, baseline value and its interaction with visit, sex, Caucasian origin, product use pattern category and its interaction with visit, and other baseline covariates relevant for the specific clinical risk endpoint as fixed effect factors and site as a random effect.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentrations of Soluble Intercellular Adhesion Molecule 1 (sICAM-1).</title>
        <description>Concentrations (ng/mL) measured in serum. Geometric Mean values are provided as descriptive statistics.</description>
        <time_frame>52 weeks</time_frame>
        <population>Full Analysis Set - As Exposed Analysis (FAS-EX). Some participants were excluded from analysis for protocol deviations (including, but not limited to, missing measurements).</population>
        <group_list>
          <group group_id="O1">
            <title>THS 2.2 Use</title>
            <description>The &quot;THS 2.2 use&quot; product use category was defined as THS use of 70% or more over the entire analysis period.&#xD;
(≥1 THS 2.2 or CC, and ≥70% THS 2.2 use over the analysis period, and ≥70% THS 2.2 use on &gt;50% of days in the analysis period.)</description>
          </group>
          <group group_id="O2">
            <title>CC Use</title>
            <description>The &quot;CC use&quot; product use category was defined as THS use of less than 1% over the entire analysis period.&#xD;
(≥1 THS 2.2 or CC use, and &lt;1% THS 2.2 use over the entire analysis period and &lt;1% THS 2.2 use on ≥ 50% of days in the analysis period.)</description>
          </group>
          <group group_id="O3">
            <title>Dual Use</title>
            <description>The &quot;Dual use&quot; product use category was defined as THS use of less than 70% over the entire analysis period.&#xD;
(≥ 1 THS 2.2 or CC and, 1% ≤THS 2.2 &lt;70% over the analysis period, or THS 2.2-use and CC use categories do not apply to 50% of these days.)</description>
          </group>
          <group group_id="O4">
            <title>Other Use</title>
            <description>&quot;Other use&quot; refers to any other product use over the entire analysis period. (Subjects with missing product use data, subjects using e-cigarettes or other tobacco products, quitters, or subjects who switched across different use patterns.)</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of Soluble Intercellular Adhesion Molecule 1 (sICAM-1).</title>
          <description>Concentrations (ng/mL) measured in serum. Geometric Mean values are provided as descriptive statistics.</description>
          <population>Full Analysis Set - As Exposed Analysis (FAS-EX). Some participants were excluded from analysis for protocol deviations (including, but not limited to, missing measurements).</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="315"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246" lower_limit="230" upper_limit="263"/>
                    <measurement group_id="O2" value="258" lower_limit="244" upper_limit="272"/>
                    <measurement group_id="O3" value="269" lower_limit="252" upper_limit="286"/>
                    <measurement group_id="O4" value="255" lower_limit="222" upper_limit="292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis will determine the effect of THS 2.2 compared to CC at Month 12 on the components of the &quot;smokers' health profile&quot;. This study has no formal pre-specified hypotheses associated with the study objectives. Estimates of THS 2.2 effect will be presented by mean of relative reduction of sICAM-1 levels between CC and THS 2.2 and related 95% CI.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% Relative Reduction</param_type>
            <param_value>3.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0231</ci_lower_limit>
            <ci_upper_limit>6.10</ci_upper_limit>
            <estimate_desc>Derived as 100 x (1 - Geometric LS Mean Ratio)</estimate_desc>
            <other_analysis_desc>Mixed model conducted on log-transformed values with visit, log-transformed baseline value and its interaction with visit, sex, Caucasian origin, product use pattern category and its interaction with visit, and other baseline covariates relevant for the specific clinical risk endpoint as fixed effect factors and site as a random effect</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentrations of 11-dehydrothromboxane B2 (11-DTXB2).</title>
        <description>Concentrations measured in urine and expressed as concentration adjusted for creatinine (pg/mg creat). Geometric Mean values are provided as descriptive statistics.</description>
        <time_frame>52 weeks</time_frame>
        <population>Full Analysis Set - As Exposed Analysis (FAS-EX). Some participants were excluded from analysis for protocol deviations (including, but not limited to, missing measurements).</population>
        <group_list>
          <group group_id="O1">
            <title>THS 2.2 Use</title>
            <description>The &quot;THS 2.2 use&quot; product use category was defined as THS use of 70% or more over the entire analysis period.&#xD;
(≥1 THS 2.2 or CC, and ≥70% THS 2.2 use over the analysis period, and ≥70% THS 2.2 use on &gt;50% of days in the analysis period.)</description>
          </group>
          <group group_id="O2">
            <title>CC Use</title>
            <description>The &quot;CC use&quot; product use category was defined as THS use of less than 1% over the entire analysis period.&#xD;
(≥1 THS 2.2 or CC use, and &lt;1% THS 2.2 use over the entire analysis period and &lt;1% THS 2.2 use on ≥ 50% of days in the analysis period.)</description>
          </group>
          <group group_id="O3">
            <title>Dual Use</title>
            <description>The &quot;Dual use&quot; product use category was defined as THS use of less than 70% over the entire analysis period.&#xD;
(≥ 1 THS 2.2 or CC and, 1% ≤THS 2.2 &lt;70% over the analysis period, or THS 2.2-use and CC use categories do not apply to 50% of these days.)</description>
          </group>
          <group group_id="O4">
            <title>Other Use</title>
            <description>&quot;Other use&quot; refers to any other product use over the entire analysis period. (Subjects with missing product use data, subjects using e-cigarettes or other tobacco products, quitters, or subjects who switched across different use patterns.)</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of 11-dehydrothromboxane B2 (11-DTXB2).</title>
          <description>Concentrations measured in urine and expressed as concentration adjusted for creatinine (pg/mg creat). Geometric Mean values are provided as descriptive statistics.</description>
          <population>Full Analysis Set - As Exposed Analysis (FAS-EX). Some participants were excluded from analysis for protocol deviations (including, but not limited to, missing measurements).</population>
          <units>pg/mg creat</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="312"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="582" lower_limit="518" upper_limit="654"/>
                    <measurement group_id="O2" value="586" lower_limit="538" upper_limit="638"/>
                    <measurement group_id="O3" value="595" lower_limit="510" upper_limit="693"/>
                    <measurement group_id="O4" value="536" lower_limit="396" upper_limit="727"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis will determine the effect of THS 2.2 compared to CC at Month 12 on the components of the &quot;smokers' health profile&quot;. This study has no formal pre-specified hypotheses associated with the study objectives. Estimates of THS 2.2 effect will be presented by mean of relative reduction of 11-DTXB2 levels between CC and THS 2.2 and related 95% CI.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% Relative Reduction</param_type>
            <param_value>3.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.74</ci_lower_limit>
            <ci_upper_limit>14.3</ci_upper_limit>
            <estimate_desc>Derived as 100 x (1-Geometric LS Mean Ratio)</estimate_desc>
            <other_analysis_desc>Mixed model conducted on log-transformed values with visit, log-transformed baseline value and its interaction with visit, sex, Caucasian origin, product use pattern category and its interaction with visit, and other baseline covariates relevant for the specific clinical risk endpoint as fixed effect factors and site as a random effect</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentrations of 8-epi-prostaglandin F2α (8-epi-PGF2α).</title>
        <description>Concentrations measured in urine and expressed as concentration adjusted for creatinine (pg/mg creat). Geometric Mean values are provided as descriptive statistics.</description>
        <time_frame>52 weeks</time_frame>
        <population>Full Analysis Set - As Exposed Analysis (FAS-EX). Some participants were excluded from analysis for protocol deviations (including, but not limited to, missing measurements).</population>
        <group_list>
          <group group_id="O1">
            <title>THS 2.2 Use</title>
            <description>The &quot;THS 2.2 use&quot; product use category was defined as THS use of 70% or more over the entire analysis period.&#xD;
(≥1 THS 2.2 or CC, and ≥70% THS 2.2 use over the analysis period, and ≥70% THS 2.2 use on &gt;50% of days in the analysis period.)</description>
          </group>
          <group group_id="O2">
            <title>CC Use</title>
            <description>The &quot;CC use&quot; product use category was defined as THS use of less than 1% over the entire analysis period.&#xD;
(≥1 THS 2.2 or CC use, and &lt;1% THS 2.2 use over the entire analysis period and &lt;1% THS 2.2 use on ≥ 50% of days in the analysis period.)</description>
          </group>
          <group group_id="O3">
            <title>Dual Use</title>
            <description>The &quot;Dual use&quot; product use category was defined as THS use of less than 70% over the entire analysis period.&#xD;
(≥ 1 THS 2.2 or CC and, 1% ≤THS 2.2 &lt;70% over the analysis period, or THS 2.2-use and CC use categories do not apply to 50% of these days.)</description>
          </group>
          <group group_id="O4">
            <title>Other Use</title>
            <description>&quot;Other use&quot; refers to any other product use over the entire analysis period. (Subjects with missing product use data, subjects using e-cigarettes or other tobacco products, quitters, or subjects who switched across different use patterns.)</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of 8-epi-prostaglandin F2α (8-epi-PGF2α).</title>
          <description>Concentrations measured in urine and expressed as concentration adjusted for creatinine (pg/mg creat). Geometric Mean values are provided as descriptive statistics.</description>
          <population>Full Analysis Set - As Exposed Analysis (FAS-EX). Some participants were excluded from analysis for protocol deviations (including, but not limited to, missing measurements).</population>
          <units>pg/mg creat</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="312"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="307" lower_limit="279" upper_limit="338"/>
                    <measurement group_id="O2" value="327" lower_limit="307" upper_limit="348"/>
                    <measurement group_id="O3" value="326" lower_limit="293" upper_limit="362"/>
                    <measurement group_id="O4" value="364" lower_limit="289" upper_limit="458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis will determine the effect of THS 2.2 compared to CC at Month 12 on the components of the &quot;smokers' health profile&quot;. This study has no formal pre-specified hypotheses associated with the study objectives. Estimates of THS 2.2 effect will be presented by mean of relative reduction of 8-epi-PGF2α levels between CC and THS 2.2 and related 95% CI.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% Relative Reduction</param_type>
            <param_value>7.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.03</ci_lower_limit>
            <ci_upper_limit>14.7</ci_upper_limit>
            <estimate_desc>Derived as 100 x (1 - Geometric LS Mean Ratio)</estimate_desc>
            <other_analysis_desc>Mixed model conducted on log-transformed values with visit, log-transformed baseline value and its interaction with visit, sex, Caucasian origin, product use pattern category and its interaction with visit, and other baseline covariates relevant for the specific clinical risk endpoint as fixed effect factors and site as a random effect.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentrations of Total 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (Total NNAL).</title>
        <description>Concentrations measured in urine and expressed as concentration adjusted for creatinine (pg/mg creat). Geometric Mean values are provided as descriptive statistics.</description>
        <time_frame>52 weeks</time_frame>
        <population>Full Analysis Set - As Exposed Analysis (FAS-EX). Some participants were excluded from analysis for protocol deviations (including, but not limited to, missing measurements).</population>
        <group_list>
          <group group_id="O1">
            <title>THS 2.2 Use</title>
            <description>The &quot;THS 2.2 use&quot; product use category was defined as THS use of 70% or more over the entire analysis period.&#xD;
(≥1 THS 2.2 or CC, and ≥70% THS 2.2 use over the analysis period, and ≥70% THS 2.2 use on &gt;50% of days in the analysis period.)</description>
          </group>
          <group group_id="O2">
            <title>CC Use</title>
            <description>The &quot;CC use&quot; product use category was defined as THS use of less than 1% over the entire analysis period.&#xD;
(≥1 THS 2.2 or CC use, and &lt;1% THS 2.2 use over the entire analysis period and &lt;1% THS 2.2 use on ≥ 50% of days in the analysis period.)</description>
          </group>
          <group group_id="O3">
            <title>Dual Use</title>
            <description>The &quot;Dual use&quot; product use category was defined as THS use of less than 70% over the entire analysis period.&#xD;
(≥ 1 THS 2.2 or CC and, 1% ≤THS 2.2 &lt;70% over the analysis period, or THS 2.2-use and CC use categories do not apply to 50% of these days.)</description>
          </group>
          <group group_id="O4">
            <title>Other Use</title>
            <description>&quot;Other use&quot; refers to any other product use over the entire analysis period. (Subjects with missing product use data, subjects using e-cigarettes or other tobacco products, quitters, or subjects who switched across different use patterns.)</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of Total 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (Total NNAL).</title>
          <description>Concentrations measured in urine and expressed as concentration adjusted for creatinine (pg/mg creat). Geometric Mean values are provided as descriptive statistics.</description>
          <population>Full Analysis Set - As Exposed Analysis (FAS-EX). Some participants were excluded from analysis for protocol deviations (including, but not limited to, missing measurements).</population>
          <units>pg/mg creat</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="312"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133" lower_limit="105" upper_limit="168"/>
                    <measurement group_id="O2" value="269" lower_limit="238" upper_limit="305"/>
                    <measurement group_id="O3" value="253" lower_limit="207" upper_limit="309"/>
                    <measurement group_id="O4" value="304" lower_limit="214" upper_limit="431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis will determine the effect of THS 2.2 compared to CC at Month 12 on the components of the &quot;smokers' health profile&quot;. This study has no formal pre-specified hypotheses associated with the study objectives. Estimates of THS 2.2 effect will be presented by mean of relative reduction of Total NNAL levels between CC and THS 2.2 and related 95% CI.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% Relative Reduction</param_type>
            <param_value>46.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>36.2</ci_lower_limit>
            <ci_upper_limit>54.8</ci_upper_limit>
            <estimate_desc>Derived as 100 x (1 - Geometric LS Mean Ratio)</estimate_desc>
            <other_analysis_desc>Mixed model conducted on log-transformed values with visit, log-transformed baseline value and its interaction with visit, sex, Caucasian origin, product use pattern category and its interaction with visit, and other baseline covariates relevant for the specific clinical risk endpoint as fixed effect factors and site as a random effect</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Levels of Carboxyhemoglobin (COHb).</title>
        <description>Carboxyhemoglobin (COHb) is assayed from whole blood. Expressed as % of saturation of hemoglobin. Geometric Mean values are provided as descriptive statistics.</description>
        <time_frame>52 weeks</time_frame>
        <population>Full Analysis Set - As Exposed Analysis (FAS-EX). Some participants were excluded from analysis for protocol deviations (including, but not limited to, missing measurements).</population>
        <group_list>
          <group group_id="O1">
            <title>THS 2.2 Use</title>
            <description>The &quot;THS 2.2 use&quot; product use category was defined as THS use of 70% or more over the entire analysis period.&#xD;
(≥1 THS 2.2 or CC, and ≥70% THS 2.2 use over the analysis period, and ≥70% THS 2.2 use on &gt;50% of days in the analysis period.)</description>
          </group>
          <group group_id="O2">
            <title>CC Use</title>
            <description>The &quot;CC use&quot; product use category was defined as THS use of less than 1% over the entire analysis period.&#xD;
(≥1 THS 2.2 or CC use, and &lt;1% THS 2.2 use over the entire analysis period and &lt;1% THS 2.2 use on ≥ 50% of days in the analysis period.)</description>
          </group>
          <group group_id="O3">
            <title>Dual Use</title>
            <description>The &quot;Dual use&quot; product use category was defined as THS use of less than 70% over the entire analysis period.&#xD;
(≥ 1 THS 2.2 or CC and, 1% ≤THS 2.2 &lt;70% over the analysis period, or THS 2.2-use and CC use categories do not apply to 50% of these days.)</description>
          </group>
          <group group_id="O4">
            <title>Other Use</title>
            <description>&quot;Other use&quot; refers to any other product use over the entire analysis period. (Subjects with missing product use data, subjects using e-cigarettes or other tobacco products, quitters, or subjects who switched across different use patterns.)</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of Carboxyhemoglobin (COHb).</title>
          <description>Carboxyhemoglobin (COHb) is assayed from whole blood. Expressed as % of saturation of hemoglobin. Geometric Mean values are provided as descriptive statistics.</description>
          <population>Full Analysis Set - As Exposed Analysis (FAS-EX). Some participants were excluded from analysis for protocol deviations (including, but not limited to, missing measurements).</population>
          <units>percent change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="257"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.59" lower_limit="2.24" upper_limit="3.01"/>
                    <measurement group_id="O2" value="4.06" lower_limit="3.77" upper_limit="4.38"/>
                    <measurement group_id="O3" value="3.92" lower_limit="3.44" upper_limit="4.46"/>
                    <measurement group_id="O4" value="5.22" lower_limit="4.47" upper_limit="6.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis will determine the effect of THS 2.2 compared to CC at Month 12 on the components of the &quot;smokers' health profile&quot;. This study has no formal pre-specified hypotheses associated with the study objectives. Estimates of THS 2.2 effect will be presented by mean of relative reduction of COHb levels between CC and THS 2.2 and related 95% CI.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% Relative Reduction</param_type>
            <param_value>31.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>23.3</ci_lower_limit>
            <ci_upper_limit>39.1</ci_upper_limit>
            <estimate_desc>Derived as 100 x (1 - Geometric LS Mean Ratio)</estimate_desc>
            <other_analysis_desc>Mixed model conducted on log-transformed values with visit, log-transformed baseline value and its interaction with visit, sex, Caucasian origin, product use pattern category and its interaction with visit, and other baseline covariates relevant for the specific clinical risk endpoint as fixed effect factors and site as a random effect.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 months (from March 2015 to September 2016)</time_frame>
      <desc>Of the 984 subjects who started the original study (NCT02396381), 20 subjects without a valid safety assessment and 24 subjects from a site terminated for non-GCP compliance were excluded from the safety population (N=940). The safety population comprised the 857 subjects of the Full Analysis Set - As Exposed (FAS-EX), who had at least one record of reported product use post randomization, and 83 subjects who were randomized and had at least 1 valid safety assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>THS 2.2 Use</title>
          <description>The &quot;THS 2.2 use&quot; product use category was defined as THS use of 70% or more over the entire analysis period.&#xD;
(≥1 THS 2.2 or CC, and ≥70% THS 2.2 use over the analysis period, and ≥70% THS 2.2 use on &gt;50% of days in the analysis period.)</description>
        </group>
        <group group_id="E2">
          <title>CC Use</title>
          <description>The &quot;CC use&quot; product use category was defined as THS use of less than 1% over the entire analysis period.&#xD;
(≥1 THS 2.2 or CC use, and &lt;1% THS 2.2 use over the entire analysis period and &lt;1% THS 2.2 use on ≥ 50% of days in the analysis period.)</description>
        </group>
        <group group_id="E3">
          <title>Dual Use</title>
          <description>The &quot;Dual use&quot; product use category was defined as THS use of less than 70% over the entire analysis period.&#xD;
(≥ 1 THS 2.2 or CC and, 1% ≤THS 2.2 &lt;70% over the analysis period, or THS 2.2-use and CC use categories do not apply to 50% of these days.)&#xD;
.</description>
        </group>
        <group group_id="E4">
          <title>Other Use</title>
          <description>&quot;Other use&quot; refers to any other product use over the entire analysis period. (Subjects with missing product use data, subjects using e-cigarettes or other tobacco products, quitters, or subjects who switched across different use patterns.)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="434"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis with Peritonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Cellulitis staphylococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Epiglottitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Urosepsis with Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Pyelonephritis Acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head injury with Seizure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Rib fracture, Clavicle fracture, Pulmonary contusion, Pleural effusion, and Traumatic Hemothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" events="5" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Foot Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Vertebral osteophyte with Cervical Myelopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Metastases to small intestine with Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alchohol abuse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Bereavement and Adjustment Disorder with Depressed Mood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="434"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="434"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="434"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="25" subjects_affected="21" subjects_at_risk="241"/>
                <counts group_id="E2" events="45" subjects_affected="40" subjects_at_risk="434"/>
                <counts group_id="E3" events="14" subjects_affected="11" subjects_at_risk="159"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="241"/>
                <counts group_id="E2" events="28" subjects_affected="26" subjects_at_risk="434"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="241"/>
                <counts group_id="E2" events="40" subjects_affected="26" subjects_at_risk="434"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="159"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>We confirm we have the contractual provisions in place which specify that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.&#xD;
The Intellectual Property rights and research results from the present study belong to the Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christelle Haziza</name_or_title>
      <organization>Philip Morris Products S.A.</organization>
      <phone>+41 58 242 11 11</phone>
      <email>christelle.haziza@pmi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

